Ratings by BofA Securities (Greg Harrison)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/14/2024 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Beam Therapeutics Inc | BEAM | Downgrade | Neutral (Buy) |
29.79 (23.47) |
-21.22% | Details | |
| 8/3/2023 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 7/17/2023 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2023 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2023 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 5/1/2023 | Stoke Therapeutics | STOK | Upgrade | Neutral (Underperform) |
8.89 (11.25) |
26.55% | Details | |
| 3/29/2023 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
18.96 (11.43) |
-39.72% | Details | |
| 1/6/2023 | Alector Inc. | ALEC | Downgrade | Neutral (Buy) |
8.76 (5.34) |
-39.04% | Details | |
| 1/6/2023 | Stoke Therapeutics | STOK | Downgrade | Underperform (Buy) |
9.32 (11.25) |
20.71% | Details | |
| 12/23/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2022 | Editas Medicine | EDIT | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2022 | Senti Biosciences, Inc. | SNTI | New Coverage | Buy (N/A) |
1.40 (0.30) |
-78.57% | Details | |
| 9/29/2022 | Editas Medicine | EDIT | New Coverage | Neutral (N/A) |
13.40 (5.46) |
-59.25% | Details | |
| 9/12/2022 | Neoleukin Therapeutics | NLTX | Downgrade | Underperform (Buy) |
1.09 (3.49) |
220.18% | Details | |
| 9/2/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 8/30/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2022 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2022 | Intellia Therapeutics | NTLA | New Coverage | Buy (N/A) |
40.93 (21.53) |
-47.4% | Details | |
| 6/8/2022 | Radius Health | RDUS | Upgrade | Neutral (Underperform) |
7.10 (17.64) |
148.45% | Details | |
| 6/8/2022 | Iveric Bio | ISEE | New Coverage | Buy (N/A) |
10.98 (39.95) |
263.84% | Details | |
| 5/26/2022 | Liquidia Technologies | LQDA | New Coverage | Buy (N/A) |
3.65 (12.95) |
254.79% | Details | |
| 5/23/2022 | Athersys | ATHX | Downgrade | Underperform (Neutral) |
0.26 (0.10) |
-61.54% | Details | |
| 5/20/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2022 | Nektar Therapeutics | NKTR | Maintain | Underperform (N/A) |
|
Details | ||
| 3/16/2022 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2022 | Athersys | ATHX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/15/2022 | Neoleukin Therapeutics | NLTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2022 | Nektar Therapeutics | NKTR | Downgrade | Underperform (Neutral) |
10.63 (1.42) |
-86.64% | Details | |
| 2/25/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2022 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 1/11/2022 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2021 | Radius Health | RDUS | New Coverage | Underperform (N/A) |
16.07 (17.64) |
9.77% | Details | |
| 12/3/2021 | Agios Pharma | AGIO | New Coverage | Buy (N/A) |
34.81 (31.81) |
-8.62% | Details | |
| 12/3/2021 | Stoke Therapeutics | STOK | New Coverage | Buy (N/A) |
23.85 (11.25) |
-52.83% | Details | |
| 11/19/2021 | Athersys | ATHX | Downgrade | Neutral (Buy) |
1.12 (0.10) |
-91.07% | Details | |
| 10/29/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2021 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
15.78 (1.42) |
-91% | Details | |
| 9/10/2021 | Beam Inc | BEAM | New Coverage | Buy (N/A) |
108.00 (23.47) |
-78.27% | Details | |
| 8/17/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2021 | Neoleukin Therapeutics | NLTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2020 | Rocket Pharmaceuticals | RCKT | New Coverage | Buy (N/A) |
21.31 (23.67) |
11.07% | Details | |
| 6/25/2020 | Athersys | ATHX | New Coverage | Buy (N/A) |
2.22 (0.10) |
-95.5% | Details |
